Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune SA is advancing its pipeline of innovative therapies targeting neurodegenerative diseases with a focus on precision medicine through proprietary technology platforms. Notably, the company's PD active immunotherapy, ACI-7104.056, has shown a significant 20x increase in antibodies against pathogenic variants, with promising correlational results related to neuronal stability and CNS antibody levels. Additionally, the anticipated results from the ACI-24 plaque removal data are viewed as a pivotal catalyst that could position the company favorably in treating high-risk Alzheimer's disease patients.

Bears say

AC Immune SA reported a significant net operating loss of CHF 16.2 million for the most recent quarter, contributing to an annual net loss of CHF 70.4 million for the year 2025. The company is confronted with typical industry risks including potential negative clinical trial outcomes, safety concerns, and regulatory uncertainties that could severely impact its development programs. Additionally, the increasing complexity and price sensitivity of commercial markets for its product candidates raise further concerns about the company's financial sustainability and future profitability.

AC Immune (ACIU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.